Ryan & Maniskas, LLP Announces Investigation of Trubion Pharmaceuticals, Inc.
13 Agosto 2010 - 3:20PM
Business Wire
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/trbn) is
investigating potential claims against the board of directors of
Trubion Pharmaceuticals, Inc. ("Trubion" or the "Company")
(NASDAQ:TRBN) concerning possible breaches of fiduciary duty and
other violations of law related to the Company’s entry into an
agreement to be acquired by Emergent BioSolutions Inc. (“Emergent”)
in a transaction valued at approximately $96.8 million.
Our investigation concerns possible breaches of fiduciary duty
and other violations of law related to approval of the transaction
by Company’s board of directors; in particular, whether the Company
undertook a fair process to obtain fair consideration for all
shareholders of Trubion. For more information regarding our
investigation, please contact Ryan & Maniskas, LLP (Richard A.
Maniskas, Esquire) toll-free at (877) 316-3218 or by email at
rmaniskas@rmclasslaw.com or visit:
www.rmclasslaw.com/cases/trbn.
Under the proposed agreement, each share of Trubion common stock
will be converted into the right to receive $1.365 per share in
cash and 0.1641 shares of Emergent stock. In addition, Trubion
shareholders will receive one contingent value right ("CVR") per
share, which will entitle the holder to receive cash payments based
upon the achievement of certain milestones. The total potential
aggregate value of the CVRs is $38.7 million over a three year
period.
If you own shares of Trubion and would like to learn more about
these claims or if you wish to discuss these matters and have any
questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign
up online, visit: www.rmclasslaw.com/cases/trbn. You may also email
Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information
about class action cases in general, please visit our website:
www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan and Maniskas, LLP is devoted to protecting the interests
of individual and institutional investors in shareholder actions in
state and federal courts nationwide.
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Trubion Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Ryan & Maniskas, LLP Artículos de Noticias